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 BRIEF REPORT 
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 Abstract 
 Objectives. Circadian rhythms are patterns in behavioural and physiological measures that recur on a daily basis and are 
driven by an endogenous circadian timekeeping system whose molecular machinery consists of a number of clock genes. 
The typical anti-psychotic haloperidol has previously been shown to induce signifi cant defi ciencies in circadian timing in 
patients. In this study we examined the impact of haloperidol treatment on molecular components of the circadian clock 
in the mouse brain.  Methods. We examined how haloperidol treatment, either acute (both at day and night) or chronically 
over 14 days, alters the expression of three clock gene protein products (PER1, PER2, BMAL1) across the mouse brain 
by means of immunohistochemistry.  Results. Chronic haloperidol treatment signifi cantly decreases the expression levels of 
PER1 in a number of brain areas, including the hippocampus, the prefrontal and cingulate cerebral cortex and the par-
aventricular nucleus of the hypothalamus. PER2 expression was only altered in the dentate gyrus and the CA3, and BMAL1 
expression was only altered in the paraventricular nucleus of the hypothalamus.  Conclusion. These data indicate that 
haloperidol has the potential to alter circadian rhythms via modulation of circadian clock gene expression. 
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 Introduction 
 The temporal regulation of physiological and behav-
ioural processes with near 24 periods is driven by 
the circadian timekeeping system consisting of a 
master pacemaker located in the suprachiasmatic 
nucleus (SCN) of the hypothalamus, with other 
brain and peripheral sites also possessing circadian 
clocks with varying abilities to maintain circadian 
time in an autonomous fashion (Hastings et al. 
2008). The molecular basis for circadian rhythm 
generation depends on a panel of clock genes, which 
regulate their own expression as well as driving the 
expression of clock controlled outputs. These clock 
genes include  Per1, Per2, Bmal1, Clock, Cry1 and 
 Cry2 , amongst others. Recent studies have reported 
rhythmic expression of clock genes in various parts 
of the mammalian brain such as the hippocampus, 
amygdala and the dopaminergic midbrain (Guilding 
and Piggins 2007). 
 Circadian rhythm disturbance has been described 
in many psychiatric disorders (Benca et al. 2009). 
There are a number studies reporting that patients 
with schizophrenia display markedly abnormal circa-
dian rhythms (e.g., Martin et al. 2005). However, it 
has been postulated that in patients treated with typ-
ical anti-psychotics, such as haloperidol, this circadian 
disturbance may be, at least in part, treatment-related, 
perhaps due to lowering arousal and activity levels 
(Wirz-Justice et al. 1997, 2001). Interestingly, similar 
circadian rhythm disturbance has been reported in 
patients with Gilles de la Tourette syndrome (Ayalon 
et al. 2002) and Alzheimer ’ s disease (Wirz-Justice 
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compliance with the European Communities Coun-
cil Directive (86/609/EEC). 
 Immunohistochemistry 
 Brains underwent an antigen-unmasking procedure 
by overnight incubation in 0.1 M citrate buffer (pH 
4.5) followed by 2.5 min heating in a microwave oven 
at 700 W followed by cryoprotected in sucrose (30%) 
for a further 24 h, and then sectioned at 30  μ m (four 
sets of serial sections) on a freezing stage microtome. 
Free-fl oating sections were processed via a standard 
avidin-biotin complex/nickel-DAB immunohisto-
chemical protocol. Primary antibodies used in this 
study were polyclonal antibodies raised in rabbit 
against PER1, PER2 and BMAL1 (all Santa Cruz 
Biotechnology, Germany) and were all used at a dilu-
tion of 1:500. The use and specifi city of these anti-
bodies in immunohistochemistry in the mouse brain 
has previously been described (Koyanagi and Ohdo 
2002; Borgs et al. 2009; Wyse and Coogan 2010). 
Further to this, for the PER1 and PER2 antibodies, 
the immunising peptides were used for adsorbtion 
control, resulting in blocking of immunostaining 
(data not shown; the immunising peptide for the 
BMAL1 antibody was not available). Sections for 
each antigen were reacted for standardized lengths of 
time to allow for uniform intensity of staining across 
experimental groups. Sections were then mounted 
onto gelatin-coated slides, dried, dehydrated, cleared 
in Histoclear (National Diagnostics, UK), and cov-
erslipped using Entellan (Merck, UK). 
 Image analysis and statistics 
 Levels of immunostaining were densitometricaly ass-
essed using the Scion Image 4.2 software (Scion Cor-
poration, Frederick, MD). Photographs of the regions 
of interest were taken using a digital camera mounted 
on an Olympus BX-51 microscope. Regions of interest 
were defi ned as by the mouse brain atlas of Paxinos 
and Franklin (2004). Background levels of staining in 
non-specifi cally stained adjoining regions were sub-
tracted for each region of interest, and stain density 
within a user-defi ned region of the unilateral area of 
interest was analysed by measurement of optical den-
sity. At least fi ve photographs per animal were quanti-
tated for each brain region. Statistical analysis was 
carried out on SPSS (www.spss.com) on a PC using 
two-way ANOVAs (with treatment (six levels) and 
brain area (12 levels) as the factors) as well as with 
one-way ANOVAs with a priori testing (the halo peridol 
treated groups compared to their respective saline con-
trols for each specifi c brain region, as well as day acute 
control saline vs. night acute control saline):  P  0.05 
et al. 2000) treated with haloperidol. Further, in the 
limited number of studies where such interventions 
were possible, switching from typical to atypical 
(e.g., clozapine) antipsychotics ameliorated the dete-
rioration in circadian rhythmicity (Wirz-Justice et al. 
1997, 2000). 
 A possible mechanism via which haloperidol and 
other typical antipsychotics disrupt circadian 
rhythms involves perturbation of the molecular 
components of the circadian clock. A number of 
psychoactive drugs have been described to modu-
late clock gene expression in various brain regions 
(Manev and Uz 2006). In the mouse SCN halo-
peridol leads to a phase-independent upregulation 
of  Per1 across the diurnal cycle following a single 
treatment (Viyoch et al. 2005). In the present study 
we have examined whether haloperidol, adminis-
tered in either an acute or a chronic manner, alters 
the expression of three clock gene products (PER1, 
PER2 and BMAL1) in a number of sites in the 
mouse brain. While haloperidol is no longer widely 
used in the clinic except for severe cases (Joy et al. 
2006) it remains an important tool to investigate 
effects of antidopaminergic substances. This is 
important since some of the modern atypicals (such 
as risperidone and amisulpride) still exhibit consid-
erable antidopaminergic properties (e.g., Moller 
2005). Thus, in the current study we set out to 
examine if there were molecular correlates in mice 
of the circadian rhythm disruption observed in 
patients treated with haloperidol. 
 Methods 
 Animals 
 Two- to three-month-old male C57/Bl6 mice, main-
tained under a 12/12-h light/dark cycle with water 
and food available ad libitum in constant tempera-
ture and humidity were used. Upon sampling, brains 
were removed rapidly and frozen, prior to being fi xed 
in 4% paraformaldehyde. Animals received intrap-
eritoneal injection of haloperidol (5 mg/kg) at Zeit-
geber Time (ZT) 3 (where ZT0 is lights on) and 
were sampled 6 h later (ZT9). Acutely treated ani-
mals received a single dose of haloperidol, chroni-
cally treated animals received a daily dose for 14 
days, and were sampled 6 h following the fi nal treat-
ment (ZT9). Control animals either received a single 
dose of 0.9% saline or a daily injection of saline for 
14 days. There were a further two treatment groups, 
which either received saline or haloperidol 2 h after 
lights out (ZT14) and were sampled 6 h later (ZT20). 
Group size for each of the six treatments was six to 
seven. Night-time sampling was conducted under 
dim red light. The experimental protocols were in 
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PER1: day-time treatment elicited a signifi cant sup-
pression only in the CC, whilst night-time treatment 
enhanced expression signifi cantly in the PFC-PL and 
the CC. The SCN did not show any signifi cant change 
in PER1 expression following any of the haloperidol 
treatment schedules. There were signifi cant day/night 
differences between the acute saline control groups in 
the SCN, the CC, the VTA, the CPu and the CeA. 
 For PER2 immunoreactivity, the effects of halo-
peridol treatment were less marked. Chronic treat-
ment resulted in signifi cant upregulation of PER2 in 
the CA3 ( P   0.05) and the DG ( P   0.01), whilst 
daytime acute treatment did not signifi cantly alter 
the expression of PER2 in any of the regions exam-
ined (Figure 2B). Night-time acute treatment 
resulted in an upregulation of PER2 immunoreactiv-
ity solely in the BLA ( P   0.05). There were no 
signifi cant effects observed in the SCN. There were 
signifi cant day/night differences between the acute 
control groups in the SCN, PVN, CA3, DG and 
CPu. BMAL-1 immunoreactivity was only signifi -
cantly altered in the PVN ( P   0.05) following 
chronic haloperidol treatment (Figure 2C), with 
acute treatments in either day or night phases inef-
fective at altering its expression. There were signifi -
cant day/night differences in BMAL-1 levels in the 
PFC-IL, DG, VTA, CPu, CeA and BLA. 
 Discussion 
 This is the fi rst study to examine the effects of 
haloperidol expression on clock gene product 
was considered statistically signifi cant. The areas exam-
ined in this study were: hippocampus  – CA1, CA3 and 
dentate gyrus (DG); cerebral cortex: prefrontal infral-
imbic (ILC), prefrontal perlimbic (PLC) and medial 
cingulate (CC); amygdala: central nucles (CEA) and 
basolateral nucleus (BLA); hypothalamus: suprachias-
matic nucleus (SCN) and paraventricular nucleus 
(PVN); ventral tegmental area (VTA), caudate puta-
men (CPu). 
 Results 
 There was expression of PER1, PER2 and BMAL1 
in all of the brain areas examined, and the nature of 
the staining was predominantly nuclear (Figure 1). 
 Two-way ANOVA revealed signifi cant main effects 
of treatment, region and signifi cant region   treat-
ment interactions for PER1 and PER2 ( P   0.001 in 
all cases), whilst there was a signifi cant main effect of 
region (but not treatment) for BMAL1, and a sig-
nifi cant region   treatment interaction ( P   0.001). 
Upon further region by region analysis we found that 
PER1 was the most reactive antigen to haloperidol 
treatment (Figure 2A) and that the most common 
effects were suppression of PER1 expression follow-
ing chronic haloperidol treatment. The PVN ( P   
 0.05), PFC-IL ( P    0.005), PFC-PL ( P    0.05), 
CA1 ( P  0.01), CA3 ( P   0.001), DG ( P  0.05) 
and CC ( P  0.01) all showed signifi cantly reduced 
levels compared to controls following chronic halo-
peridol treatment. In contrast to this, the effects of 
acute haloperidol treatment were more modest on 
 
Figure 1. Sample photomicrographs of PER1 expression in the areas of interest and treatments examined in this study. For each are the 
area delineated for analysis is outlined. For the prefrontal cortex (PFC) the dotted box represent the area of prelimbic cortex examined 
and the dashed box the area of infralimbic cortex. For the hippocampus (Hippo), the dotted box is in the CA1, the dashed ellipse the 
CA3 and the solid-outline box the dentate gyrus. For the amygdala (Amyg) the dotted oval represents the basolateral amygdala and the 
dashed circle the central nucleus. The scale bar   200  μ m. 
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evidence that haloperidol may alter circadian time 
across the brain. 
 A number of studies have implicated circadian 
processes in schizophrenia (Wirz-Justice et al. 2001; 
expression in a number of brain areas. The results 
from this study, that PER1 and to a much lesser 
extent PER2 and BMAL-1, expression is altered 
in a number of these areas, provides molecular 
 
Figure 2. Semi-quantitation of photomicrographs for regulation of (A) PER1, (B) PER2 and (C) BMAL1 expression by haloperidol 
treatment. Each group (acute haloperidol day (black bars), acute haloperidol night (white bars), chronic haloperidol (hatched bars)) is 
expressed as a percentage of its respective saline group mean value. Signifi cant effects of drug treatment compared to the appropriate 
saline control group is denoted by ∗ . The regions examined were: cerebral cortex: hypothalamus: suprachiasmatic nucleus (SCN) and 
paraventricular nucleus (PVN); prefrontal infralimbic (PFC-IL), prefrontal perlimbic (PFC-PL) and medial cingulate (CC); Hippocampus  – 
CA1, CA3 and dentate gyrus (DG); amygdala: central nucles (CEA) and basolateral nucleus (BLA); ventral tegmental area (VTA), caudate 
putamen (CPu). 
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Roberstson and Fibiger 1992). The functional sig-
nifi cance of clock gene expression in many brain 
sites is incompletely understood, partly due to the 
complexity of delineating their circadian functions 
from any non-circadian functions, and partly in 
teasing apart the autonomous role of a circadian 
clock in a particular structure apart from the func-
tioning of the brain ’ s distributed circadian system 
as a whole. However, evidence is now emerging 
regarding important roles for circadian clocks in the 
functioning of extra-SCN sites: for example, the 
hippocampus expresses rhythmic patterns of clock 
genes, and disruption of these by gene knockout 
affects memory task performance and synaptic plas-
ticity (Gerstner and Yin 2010). If haloperidol alters 
the hippocampal circadian clock, which in turn con-
tributes to memory function, one might speculate 
that this effect could contribute to the deleterious 
effects of haloperidol in hippocampal-dependent 
memory (e.g., Hou et al. 2006). For a number of 
the regions examined in the present study, it is still 
somewhat speculative as to what the functional con-
sequence of rhythmic clock gene expression is, 
although one might imagine for example roles for 
the circadian clock in the prefrontal cortex in the 
temporal regulation of executive function and work-
ing memory, as has been described in humans 
(Schmidt et al. 2007). Further, alteration of the nor-
mal prefrontal circadian processes by haloperidol 
could contribute to haloperidol-induced defi cits in 
working memory (Castner et al. 2000). Therefore, 
it is conceivable that the poor profi le of haloperidol 
in ameliorating, or even worsening, neurocognitive 
defi cits may be mediated partly through effects on 
circadian processes. 
 Broader dopaminergic regulation of clock gene 
expression is evidenced by Imbesi et al. (2009) who 
report that in cultured primary striatal neurons the 
D2 class agonist quinpirole suppresses expression of 
 clock and  per1 , whilst the D1 agonist SKF38393 
enhances  clock, per1, bmal1 and  npas2 expression, 
with quinpirole also phase-shifting of PER1 expres-
sion in the striatum  in vivo . Acute exposure to cocaine 
leads to increased  per1 but not  per2 and  bmal1 expres-
sion in the hippocampus, whereas chronic cocaine 
administration increases  per1 and  per2 levels (Uz et al. 
2005). The same study shows that acute cocaine 
does not affect  per1, per2 or  bmal1 in the caudate 
putamen, but chronic cocaine does upregulate  per1 
and downregulates  per2 and  bmal1 . Whilst it is diffi -
cult to compare these results with those presented in 
this paper (haloperidol vs. cocaine, protein vs. mRNA 
expression), it is interesting to note the differential 
regulation of  per1 ,  per2 an  bmal1 , the regional speci-
fi cities of the effects and the fact that chronic treat-
ment is more effi cacious at producing alterations in 
Mansour et al. 2006), although candidate clock gene 
association studies are equivocal (e.g,. Kishi et al. 
2009b; Mansour et al. 2009). Previous studies have 
indicated interplay between the circadian system and 
typical antipsychotics. Circadian processes are known 
to infl uence haloperidol ’ s actions, with circadian 
rhythms described in haloperidol-induced catalepsy 
(Campbell and Baldessarini 1982), a principle that 
is also found for other psychoactive medications 
(Kishi et al. 2009a). Conversely, Viyoch et al. (2005) 
reported that acute haloperidol treatment increases 
the expression of  per1 in the SCN across the diurnal 
cycle, an effect that was independent of the time of 
day of the treatment and was blocked by the NMDA-
channel blocker MK801 and involved the transcrip-
tion factor CREB. The effects of haloperidol, along 
with clozapine and anxiolytics, was examined on the 
expression of  per1 and  per2 in the mouse cerebellum 
in study by Akiyama et al. (1999), with no effects of 
haloperidol treatment on either of these clock genes 
reported. In the present study we did not demon-
strate any signifi cant effect of haloperidol treatment 
on SCN expression of PER1, PER2 and BMAL1. 
Viyoch et al. (2005) report that  per1 is upregulated 
in the SCN with treatments administered across the 
diurnal cycle, and therefore it seems unlikely that we 
fail to show SCN effects by treating at an unrespon-
sive circadian phase. A possibility is that neither of 
our sampling times (ZT9, ZT20) include the early-
night peak of SCN PER1 and PER2, therefore rais-
ing the possibility that a suppression of maximal 
SCN PER1/2 levels might be missed. The results of 
Honma and Honma ’ s study (1995) of SCN lesioned 
rats showing that haloperidol can alter behavioural 
circadian rhythms mediated outside of the SCN is 
in broad agreement with our results, indicting that 
haloperidol elicits circadian effects by, in part at 
least, acting outside of the SCN. Further, the lack of 
effect on SCN clock gene product expression is in 
line with the observation that halopediol does not 
entrain rat behavioural circadian rhythms (Gillman 
et al. 2009). Other factors, such as the time between 
treatment and sampling for acutely treated animals 
(e.g., is 6 h suffi cient time to see alterations in levels 
of PER1 protein?), a disconnect between mRNA and 
protein expression and the effects of repeated doses 
for chronic treatment, may be responsible for the 
differences observed between our results in the SCN 
and those of Viyoch et al. (2005). 
 Since many brain areas are now believed to pos-
sess at least the molecular machinery required to act 
as circadian oscillators (Guilding and Piggins 2007), 
it is of particular interest to investigate the effects of 
psychoactive substances across a number of brain 
sites, including those previously shown to respond 
to a particular drug (e.g., by c-Fos expression, 
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clock gene expression than acute treatments, all fac-
ets that are reported in the current study with regards 
to haloperidol. The molecular mode of action by 
which oppossing regulation of PER1 and PER2 may 
be brought about by dopaminergic agents is not clear 
and warrants further study. One possibility is that the 
rhythmic expression of PER1 and PER2 may have 
somewhat different phasing in any given brain area 
(Feillet et al. 2008) and haloperidol-induced phase-
shifts of these rhythms may appear to have opposing 
actions (e.g., PER1 may be shifted away from its 
peak, PER2 may be shifted towards its peak). 
 Our current study indicates that haloperidol can 
alter expression of circadian clock genes in various 
sites across the brain. This potentially disruptive effect 
on the molecular mechanisms of circadian timekeep-
ing might in part explain the disruptive effects of halo-
peridol on behavioural rhythms reported in patient 
studies (Wirz-Justice et al. 1997, 2000, 2001; Ayalon 
2002), effects that are seen to persist throughout halo-
peridol monotherapy (Wirz-Justice et al. 2001). Our 
results highlight the deleterious consequences typical 
anti-psychotics may have for patients ’ circadian rhty-
hms. However, it is worth considering such negative 
effects in the light of improved sleep measures also 
reported for haloperidol in schizophrenics (Monti and 
Monti 2004), indicating possible divergent regulation 
of sleep homeostatic and circadian processes. Given 
the partial antidopaminergic properties of widely used 
atypical anti-psychotics (reported to improve circa-
dian rhythms in demented or schizophrenic patients), 
examining their effects on circadian clock gene expres-
sion will be of considerable future interest. Studies of 
rhythmic clock gene expression in patients treated 
with antipsychotics (both typical and atypical) would 
also be most revealing. 
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